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Abstract
Background: Haemodialysis in Malawi consumes a disproportionate amount of the national health budget, costing
approximately $20,000 per patient per year. Adjunctive therapeutic agents for end stage kidney disease and
laboratory services to measure standard dialysis outcomes are not routinely available. Therefore, alternative
outcome measures of the efficacy of haemodialysis in Malawi are required. We measured health related quality of
life of adult patients in Malawi treated with haemodialysis for end stage kidney disease.
Methods: We performed a cross-sectional study of patients receiving haemodialysis for end stage kidney disease at
4 dialysis centres in Malawi between 24/10/2012 and 30/11/012. Patients were included if they were >18 years of
age and had been receiving haemodialysis for >3 months. We used the Kidney Disease Quality of Life Instrument
Short Form to assess health related quality of life.
Results: We recruited 22 of 24 eligible patients (mean age 44.8 ± 16.0 years, 59.1 % male, median duration on
haemodialysis 12 months (Inter-quartile range 6–24 months)). Overall health related quality of life was low (mean
score 59.9 ± 8.8, maximum possible score 100) with the lowest scores recorded for physical health component
summary score (50.4 ± 22.8) compared to mental health component summary (61.3 ± 23.0) and kidney disease
component summary (67.9 ± 13.2). Low household income (<$4000 per year) was associated with lower mental
health component scores (adjusted r2 = 0.413, p = 0.033).
Conclusions: Quality of life of haemodialysis patients in Malawi can be easily measured using a validated
questionnaire and provides an alternative and important measure of the efficacy of haemodialysis therapy. Physical
health scores were particularly low and this may affect income generating capacity. Increased efforts are required to
improve the quality of life of haemodialysis patients in Malawi with a particular focus on the burden of physical
symptoms.
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Background
The provision of therapies for end stage kidney disease
(ESKD) presents significant financial and ethical chal-
lenges in resources limited settings. Haemodialysis has
been provided free at the point of access in the public
sector in Malawi (population 16.3 million) since 1998 at
a four-station dialysis unit at Kamuzu Central Hospital
in Lilongwe [1]. Dialysis services in Malawi expanded
between 2011 and 2012 to include an additional public
sector dialysis unit and two new dialysis units in the pri-
vate sector. The approximate cost of haemodialysis con-
sumables alone per patient per year is $20,000, which is
met entirely by the government of Malawi [2]. Despite
the expansion of dialysis services, kidney transplantation
is not performed within Malawi. Patients must access
this service in a transplant centre pre-identified and paid
for by the Malawi Ministry of Health in India which in-
curs a cost of approximately $30,000, well beyond the
means of the vast majority of the population (more than
75 % of the population of Malawi earns <$1.25 per day
[2]) and not currently paid for routinely by the Malawi
government due to chronic funding restrictions.
Additional therapeutic interventions for ESKD includ-
ing intravenous (IV) iron, erythropoietin stimulating
agents (ESA) and vitamin D receptor activating (VDRA)
compounds are not available in the public sector and the
cost of these items is beyond the reach of almost all fee
paying patients in Malawi. In addition, laboratory ser-
vices are expensive and unreliable. Consequently, access
to traditional measures used to monitor the efficacy of
haemodialysis, including Kt/V, haemoglobin, calcium,
phosphate and parathyroid hormone, are not routinely
available. Furthermore, where these measures are avail-
able, the lack of IV iron, ESA and VDRA compounds
means that these parameters are not practical measures
of the efficacy of therapy for ESKD in resource limited
settings. Thus, in such settings, alternative measures of
dialysis efficacy are required to ascertain the clinical
benefits of haemodialysis.
Health related quality of life (HRQOL), as measured
by the Kidney Disease Quality of Life Instrument Short
Form questionnaire (KDOQL-SF) is an important meas-
ure of the efficacy of dialysis and has been used to sup-
plement traditional measures of haemodialysis efficacy
in a range of settings [3–6]. In resource limited settings,
HRQOL represents an alternative and important out-
come measure of dialysis efficacy, providing a cheap and
indicative measure of the efficacy of haemodialysis at an
individual level.
There have been few studies of the HRQOL of haemo-
dialysis patients in Africa and none in Malawi. With no
routine access in Malawi to adjunctive therapies for
ESKD or traditional measures of haemodialysis efficacy,
there is a pressing need to evaluate pragmatically useful
measures of haemodialysis efficacy. Accordingly, we
studied the HRQOL of patients with ESKD treated with
haemodialysis in Malawi. The specific aim of this study
was to evaluate the HRQOL of the prevalent haemo-
dialysis population in Malawi using an internationally
validated HRQOL instrument, the KDOQL SF ques-
tionnaire which provides a quantitative assessment of
physical, mental and kidney related quality of life parame-
ters. In addition, we evaluated the effect of household




We conducted a cross-sectional study of prevalent pa-
tients with ESKD treated with haemodialysis in Malawi
between 24/10/2012 and 30/11/012. During the study
period, there were no patients receiving peritoneal dialy-
sis in Malawi. The study received approval from the Col-
lege of Medicine Research Ethics Committee (protocol
reference SP.07/12/57). The study design conformed to
STROBE guidelines (see Additional file 1). All partici-
pants provided written informed consent. Patients were
included if they were >18 years of age and, had been
treated for ESKD with haemodialysis for at least
3 months. Patient were excluded if they were unwilling
or unable to complete the questionnaire, did not provide
consent to participate in the study, missed dialysis dur-
ing the study period or were treated with haemodialysis
for acute kidney injury with a duration on haemodialysis
of less than 3 months.
Patient selection
Considering the small number of haemodialysis patients
in Malawi, we used a non-probability convenience sam-
pling method in order to recruit the maximum number
of patients possible. All patients who met the study entry
criteria from all four dialysis centres in Malawi were
approached for inclusion. These were Kamuzu Central
Hospital, Lilongwe (public sector), Queen Elizabeth Cen-
tral Hospital, Blantyre (public sector), Daeyang Luke Hos-
pital, Lilongwe (private sector) and Mwaiwathu Hospital,
Blantyre (private sector). All aspects of health care in the
public sector in Malawi including dialysis therapies are
provided free at the point access. The cost per session in
the private sector was approximately $150 per haemodi-
alysis session for dialysis consumables alone (Personal
communication, Wirima J 2012).
Data collection
We used the KDQOL-SF questionnaire (version 1.3), an
internationally validated instrument for assessing the
HRQOL of dialysis patients [7, 8] (Additional file 2). The
questionnaire consists of measures of general health as well
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as specific domains for ESKD. These specific domains are:
Physical health component summary (PCS) comprising the
following scales - physical functioning (10 items), role-
physical (4 items), bodily pain (2 items), and general health
(5 items); mental health component summary (MCS) com-
prising the following scales - fatigue/energy (4 items), social
functioning (2 items), role emotional (5 items), and mental
health (3 items) and kidney disease component summary
(KDCS) comprising the following scales - symptom/prob-
lem list (12 items), effects of kidney disease on daily life (8
items), burden of kidney disease (4 items), cognitive func-
tion (4 items), work status (2 items), sexual function (2
items), quality of social interaction (3 items), sleep (4 items),
social support (2 items), dialysis staff encouragement (2
items) and patient satisfaction (1 item). Mean scores for
three main domains (PCS, MCS and KDCS), were gener-
ated using the Hays algorithm [9]. The maximum achiev-
able score for any one domain, representing optimal
quality of life, is 100.
The KDQOL-SF questionnaire was not completely
compatible with the study setting and several subtle
changes were made to better suit the Malawian haemo-
dialysis population (See Additional file 3: Table S1). Two
members of the study team (MK and BC) translated
the questionnaire into the written local language of
Chichewa. The questionnaire was self administered
however, where necessary, patients could ask dialysis
unit staff for explanations about the meaning of questions
but neither the study team nor nursing staff influenced
the replies of patients.
We collected demographic data including age, sex,
marital, education and employment status, cause of
ESKD, presence of diabetes mellitus, dialysis vintage,
number of medications prescribed per patient, total
yearly household income (recorded in Malawi Kwacha
and then converted to US Dollars using exchange rates
valid at the time of the study), number of admission days
to hospital in the last 6 months, number of non-renal
outpatient visits to hospital in the last 6 months and
HIV status. Where available, we collected co-morbidity
data on previous cardiovascular events (myocardial in-
farction, stroke) from patient health records and patient
recall. All data were fully anonymised, stored securely
and only available to the study staff.
Statistical analysis
Demographic data is reported as mean and standard de-
viation, median with inter-quartile range or number and
percentage for categorical variables, depending on the
distribution of the data. The main outcome was the
three main domains of the KDOQL-SF questionnaire
(PCS, MCS and KDCS) and their sub-domains which
are presented as the mean score and standard deviation.
This is in line with the Hays algorithm [9] and conforms
to international reporting of these results. Comparisons
between PCS, MCS and KDCS scores were made be-
tween exposure sub-groups of age, sex, marital, educa-
tion and work status, dialysis vintage and total yearly
household income. Sub-groups were compared using a
2-tailed Student’s t test or the Mann Whitney U test
based on the distribution of the data.
We assessed the correlation between KDCS and both
PCS and MCS. The association between the exposure of
total yearly household income and the outcomes of
MCS, PCS and KDCS was assessed using linear regres-
sion modelling, adjusting for age and sex. We restricted
our analysis to these a priori confounders due to the
small sample size. Stata version 10 (www.stata.com) and
Graph Pad Prism 5.0 (www.graphpad.com) were used
for analysis. A p-value of <0.05 was considered statisti-
cally significant.
Results
During the study period, there were 35 patients receiving
haemodialysis for ESKD in Malawi. Of these, 24 (68.6 %)
were eligible for inclusion and 22 (62.3 %) were recruited
(Fig. 1). The mean age of recruited patients was 44.8 ±
16.0 years, n = 13 (59.1 %) male. The commonest cause
of ESKD was hypertension (n = 9, 40.9 %) followed by
diabetes mellitus (n = 3, 13.7 %), other causes (n = 5,
22.7 %) and unknown cause of ESKD (n = 5, 22.7 %).
Diabetes mellitus as a co-morbidity but not as the pri-
mary cause of ESKD was present in 2 (9.1 %) patients.
Demographic and clinical data
Five patients (22.7 %) received haemodialysis in the pri-
vate sector. Their demographic data did not significantly
differ from patients treated in the public sector (data not
shown). All but one patient (who received haemodialysis
three times per week) were scheduled to receive twice
weekly haemodialysis for 4 h, reflecting personal finan-
cial constraints of patients treated in the private sector
and government funding limits in the public sector. No
patients in either the public or private sector were re-
ceiving therapy with intravenous iron, ESA or VDRA
compounds. Four patients (18.2 %), all treated in the
public sector, were HIV positive and all were on anti-
retroviral therapy. No patients reported a previous
history of cardiovascular events. The mean number of
prescribed medications per patient was 3.6 ± 1.6.
The median dialysis vintage was 12 months (IQR 6–24
months). The majority of patients were married (n = 12,
54.6 %), 11 (50 %) were employed and 11 (50 %) had
attained higher than secondary education status. The
median total yearly household income was $3960 (IQR
$792–$11,880). Six patients reported no regular yearly
household income. In the 6 months prior to the study,
the median number of hospital admission days related
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to kidney disease was 6 (IQR 1–14) and the median
number of hospital out-patient visit days for non-renal
conditions was 3 (IQR 1–4).
Quality of life data
The mean overall HRQOL score from all three principal
domains was 59.9 ± 8.8. Quality of life was generally low
in all three principal domains with the lowest score
recorded in the PCS domain (Table 1). When the three
principal domains were subdivided into their component
categories, the lowest scores per category were recorded
in the PCS as Role Physical (26.1 ± 38.1), in the MCS as
Energy/Fatigue (48.2 ± 24.8) and in the KDCS as Burden
of Kidney Disease (27.0 ± 31.2) (Table 1). Principal com-
ponent domain scores (PCS, MCS and KDCS) did not
differ significantly between categories of age, sex, mari-
tal, education or employment status or dialysis vintage.
However, the mean MCS score was significantly higher
in patients with a total yearly household income >$4000
(p = 0.04) (Table 2).
The KDCS score correlated strongly and positively
with both MCS (r = 0.620, p = 0.002) and PCS (r = 0.770,
p < 0.0001) (Figs. 2 and 3). Total yearly household in-
come was associated with MCS in both crude (r2 = 0.34,
p = 0.029) and adjusted linear regression analyses (r2 =
0.41, p = 0.033). The point estimate on the MCS score
for a 1,000,000 Malawi Kwacha increase in household
income was 5.8 (95 % CI 1.0–10.5). There was no as-
sociation between PCS and KDCS and total yearly
household income (Table 3). In addition, we com-
pared our findings to those from studies using the
KDOQL-SF instrument in other settings. The scores
for KDCS and MCS were generally above while the
PCS score was in the mid-range of scores from other
global dialysis HRQOL studies (Table 4).
Discussion
This is the first study we are aware of that describes
HRQOL of patients with ESKD treated with haemodialy-
sis in a low resource setting in sub-Saharan Africa in
which dialytic frequency is lower than normal and the
most common adjunctive therapies for ESKD, beyond
haemodialysis itself, are not routinely available. The
Fig. 1 Participant recruitment schedule
Table 1 KDOQL-SF scores for principal and sub domains. Data
are mean (standard deviation), n = 22
Principal domain Sub-domain Mean (SD)
PCS mean score 50.4 ± 22.8 Physical functioning 61.1 (28.8)
Role-physical 26.1 (38.1)
Pain 56.7 (33.2)
General Health 57.8 (24.1)
MCS mean score 61.3 ± 23.0 Energy/fatigue 48.2 (24.8)
Social function 56.2 (31.3)
Role emotional 68.2 (45.4)
Emotional well-being 72.7 (23.9)
KDCS mean score 67.9 ± 13.2 Symptom/problem list 75.9 (18.6)
Effect of kidney disease 55.1 (32.6)
Burden of kidney disease 27.0 (31.2)
Cognitive function 83.0 (24.1)
Work status 36.4 (44.1)
Sexual function# 89.6 (25.5)
Quality of social interaction 87.0 (20.1)
Sleep 71.1 (20.1)
Social support 80.3 (28.5)
Dialysis staff encouragement 85.2 (23.0)
Patient satisfaction 77.3 (17.5)
# = sexual function score only answered by 6 patients. PCS physical
component summary, MCS mental component summary, KDCS kidney disease
component summary
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lowest scores in our study were recorded for physical
symptoms and in line with other studies [4, 5, 10–14],
scores for the PCS were lower than scores in the MCS
and KDCS domains. This reflects the excessive burden
of physical compared to other symptoms experienced by
patients treated with haemodialysis for ESKD. The low
scores in our study recorded in the domains of Energy/
Fatigue and Role Physical are likely to be multi-factorial
but may specifically reflect untreated anaemia associated
with ESKD. High scores were recorded for patient satis-
faction, social support and dialysis staff encouragement
which most likely reflect the efforts of clinical staff as
well as family and community members in supporting
patients treated with haemodialysis for ESKD in Malawi.
There was a strong positive correlation between KDCS
scores and both PCS and MCS scores which suggests
that addressing kidney specific components of HRQOL
has the potential to improve mental and physical health.
In contrast to other studies [4, 15], we found that, age,
sex, marital, educational or employment status and dur-
ation on haemodialysis were not associated with significant
differences in HRQOL scores. Low yearly total household
income, but not individual employment status, was
associated with lower MCS scores and may in part
Table 2 Mean scores for the 3 main domains from the KDOQL-SF instrument compared between key variables (n = 22)
Variable PCS MCS KDCS
Score p-value Score p-value Score p-value
Age <45 years (n = 11) 49.8 0.89 58.3 0.55 62.9 0.08
>45 years (n = 11) 51.1 64.4 72.9
Sex Male (n = 13) 54.1 0.38 64.0 0.52 68.1 0.93
Female (n = 9) 45.2 57.4 67.6
Marital status Married (n = 12) 56.2 0.20 68.3 0.12 70.9 0.25
Not married (n = 10) 43.6 52.9 64.3
Education status Secondary or below (n = 9) 47.1 0.58 63.4 0.73 65.5 0.52
Above secondary (n = 13) 52.8 60.0 69.4
Employment status Employed (n = 11) 51.9 0.78 66.6 0.29 70.4 0.39
Unemployed (n = 11) 49.0 56.0 65.4
Dialysis vintage <12 months (n = 10) 49.1 0.81 62.6 0.82 70.2 0.39
>12 months (n = 12) 51.6 60.3 66.0
Yearly total household income <$4000 (n = 16) 43.3 0.30 51.2 0.04 67.8 0.99
>$4000 (n = 6) 56.1 75.2 67.9
PCS physical component summary, MCS mental component summary, KDCS kidney disease component summary
Fig. 2 Correlation between KDCS and MCS components of the
KDOQL-SF questionnaire (r = 0.62, p = 0.0021). KDCS kidney disease
component summary, MCS mental component summary
Fig. 3 Correlation between KDCS and PCS components of the
KDOQL-SF questionnaire (r = 0.77, p < 0.0001). KDCS kidney disease
component summary, PCS mental component summary
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reflect personal stress as a consequence of lost oppor-
tunities for income generation due to time spent on
haemodialysis, repeated hospital admissions and lack
of employment opportunities due to reduced levels of
physical function. The very low scores recorded for
Burden of Kidney Disease and Work Status in the
KDCS domain reflect the specific and significant impact
of kidney disease and its treatment with haemodialysis on
daily life, including employment opportunities.
The scores for PCS, MCS and KDCS in our study are
similar to and in many cases better than equivalent
scores from Africa and other global studies, including
well-resourced settings where thrice weekly haemodialy-
sis, IV iron, ESA, VDRA compounds and other thera-
peutic interventions for ESKD are routinely available.
The younger age and shorter dialysis vintage in our
study may account for the finding that our HRQOL
scores were similar to or better than those in many
resource-rich settings where multiple co-morbidities, in-
creased age and longer dialysis vintage are likely to con-
tribute to reduced HRQOL. Improving, maintaining and
monitoring the HRQOL of dialysis patients is particu-
larly important since a reduction of as little as 10 points
in the MCS and PCS (but not KDCS) domains are
associated with both a significantly increased risk of
hospitalization and death [11].
The financial reality of providing a high cost, long
term and specialist service for ESKD in resource limited
settings is such that most patients will only receive
haemodialysis treatment as a stand-alone therapy for
ESKD. In addition, haemodialysis frequency will most
likely be limited by financial constraints to below the
standard practice of thrice weekly haemodialysis
sessions. The expectation in these circumstances might
be that HRQOL of life would be poor. However, our
data suggest that HRQOL in Malawi, where adjunctive
therapies are not available and twice weekly haemodialy-
sis is routine, is at least comparable to and in some cases
better than in both low and high resourced settings
(Table 4).
Furthermore, the number of patients with ESKD re-
quiring renal replacement therapy globally is estimated
at 2.05 million and in Africa alone, using a conservative
model, is estimated at 515,000 but could be as high as
949,000 [16]. The global prevalence of ESKD is predicted
to rise sharply in the next 20–30 years with the biggest
growth in low resource settings [16]. Therefore, a meas-
ure of HRQOL which is cheap, simple to administer and
comparable to other global settings represents an import-
ant outcome measure which can be employed in resource
limited settings and used to support routine laboratory
tests of dialysis efficacy where available. Our data will be
of value to patients, their families, health service providers
and clinicians in sub-Saharan Africa and globally who face
difficult financial choices in terms of both the provision of
and uptake of haemodialysis for ESKD.
The strengths of our study include the use of an inter-
nationally validated instrument for assessing HRQOL in pa-
tients treated with haemodialysis for ESKD. In line with
Bouidida et al. [8] we made minor modifications to this in-
strument to improve its applicability in Malawi. We do not
consider these changes to materially alter the content of
the questionnaire. Similar to other studies [17, 18], we ex-
cluded patients who had been on haemodialysis for less
than 3 months to ensure accurate representation of the ef-
fect of haemodialysis therapy on HRQOL. Yearly total
household income may have been affected by reporting
bias, however, any such bias will have been reduced
through the use of fully anonymised questionnaires that
were completed in private. The total number of patients in-
cluded in the study is small and given that a significant
amount of ESKD in Malawi is undetected and therefore
not treated with dialysis, our population will not be fully
representative of all cases of ESKD in Malawi. However, of
the 24 patients who met the inclusion criteria, we were able
to recruit 22 (91.7 %) and so our study accurately reflects
HRQOL in a prevalent haemodialysis population in
Table 4 Comparison of component summary scores from studies that have used the KDOQL-SF to assess health related quality of
life in end stage kidney disease patients treated with haemodialysis
Country or region
Malawi# Tunisia [10] Saudi Arabia [4] Japan [11] USA [13] Europe [11] Senegal [17] Brazil [19] Turkey [12]
PCS 50.4 49.2 52.7 44.5 33.1 35.5 44.8 60.0 62.0
MCS 61.3 60.9 54.1 41.7 46.6 42.7 54.8 68.0 71.0
KDCS 67.9 62.7 59.7 65.5 71.1 62.8 60.8 63.9 63.8
PCS physical component summary, MCS mental component summary, KDCS kidney disease component summary
#present study
Table 3 Crude and adjusted linear regression analysis of the
association between total yearly household income and MCS,
PCS and KDCS
Principal domain Crude r2 p-value Adjusted r2# p-value
PCS 0.08 0.32 0.36 0.21
MCS 0.34 0.029 0.41 0.033
KDCS 0.01 0.28 0.01 0.40
PCS physical component summary, MCS mental component summary, KDCS
kidney disease component summary
#adjusted for age and sex
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Malawi. Equally, the small number of patients included
limits the depth of our statistical analysis, precluding the in-
clusion of multiple confounders in our regression analysis.
We recognise that survivor bias may be present in the sam-
ple we selected. Furthermore, given that some patients did
not attend for dialysis during the study, perhaps due to
poor health, we were not able to record HRQOL measures
from this group, potentially leading to an overestimation of
HRQOL although given that only three patients did not at-
tend, this is unlikely to materially alter the conclusions of
the study. Furthermore, the lack of haematological and bio-
chemical data prevented us from adjusting for the effect of
these parameters, particularly anaemia, on PCS and MCS
scores. There is no pecuniary reason to suspect that
haemoglobin values materially differ across the study sites
given the lack of IV iron and EPO in Malawi as a whole.
Most haemodialysis treatment in sub-Saharan Africa is
provided in fee-paying haemodialysis units. The high cost
of IV iron, EPO and VDRA compounds means these treat-
ments are likely to be beyond the reach of the majority of
fee paying patients and so our results, even though they
only included a small number of patients treated privately
in Malawi, are generalizable to patients elsewhere in sub-
Saharan Africa who are highly likely to receive haemodi-
alysis without these adjunctive treatments.
Conclusion
The HRQOL patients treated for ESKD with haemodi-
alysis in Malawi can provide a clinically useful measure
of haemodialysis efficacy in the absence of traditional la-
boratory measures of dialysis outcomes. We remain san-
guine about the fact that HRQOL can complement but
not definitively replace the standard laboratory measures
of the efficacy of dialytic therapies. Increasing dialysis
frequency, provision of low cost, non-dialytic therapies
for ESKD and increasing employment opportunities for
patients treated with haemodialysis all have the potential
to achieve improved HRQOL. Further studies, which
should include cost effectiveness analyses, are required
to ascertain which interventions, novel and established,
can significantly improve the HRQOL of haemodialysis
patients in Malawi and other low resource settings.
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